$3.08 BillionThe market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.
$20.7 MillionTotal revenue in the last quarter.
$-11 MillionNet income is all revenues minus all expenses including taxes and interest in the last quarter.
$-0.68Earnings per share is the amount of net income that is attributed to each single share outstanding.
-Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).
-78.01xThe price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.
$-11.1 MillionEarnings before interest expenses and taxes in the last quarter.
354The number of full time employees.
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte to Participate in Piper Sandler 32nd Annual Virtual Healthcare ConferenceBusiness Wire, 6 days ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces Third Quarter 2020 Financial ResultsBusiness Wire, 27 days ago
BidaskClub cut shares of Veracyte (NASDAQ:VCYT) from a strong-buy rating to a buy rating in a report issued on Friday, BidAskClub reports. Other equities analysts also recently issued research repo...Transcript Daily, about 1 month ago